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Abstract. DNA extracted from the blood of immuno­
suppressed and immunocompromised individuals and from 
patients with infectious mononucleosis, leukaemias and 
lymphomas were studied using the Polymerase Chain 
Reaction (PCR) technique. The oligonucleotide primers used 
for the detection of the Epstein-Barr virus (EBV) amplify a 
375bp sequence from the EcoRI Β fragment of the viral 
genome. EBV specific sequences were amplified from the 
blood samples of 18 out of 65 patients, most of which were 
transplant patients (9 out of 31 ). The results confirmed the 
association of EBV with clinical disorders in immuno-
deficient and immunocompromised patients and the 
importance of PCR method in routine diagnosis. 
Introduction 
Epstein-Barr Virus (EBV) is a member of the human herpes 
virus family and the causative agent of infectious 
mononucleosis (1). EBV has a B-lymphocyte tropism and is 
strongly associated with post-transplanted lympho-
proliferative disorders, Hodgkin's disease, nasopharyngeal 
carcinoma, Burkitt's lymphoma and lymphoproliferative 
disorders of primary and secondary immunodeficiency (2,3). 
The virus, which has been detected worldwide, invades 
B-lymphocytes that have EBV receptors in common with 
receptors for the complement components. Selected epithelial 
cells of different organs bearing the same receptors may also 
become infected. Primary infection occuring in childhood is 
mostly asymptomatic but in later childhood and adolescence 
may result in lymphoproliferative diseases. In 
immunosuppressed transplant patients and in individuals 
with the acquired immunodeficiency virus, in whom there is 
a loss in T-lymphocyte mediated control of stimulated Β 
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lymphocytes, malignant lymphomas may arise from 
activation of latently EBV-infected Β lymphocytes (4). 
The detection of EBV infections is limited by the lack of 
routine laboratory techniques and diagnosis of primary or 
reactivated EBV infection is often based on serological tests 
(1,5). Recently, in vitro amplification of specific nucleic acid 
sequences by the PCR technique has been applied for the 
identification of EBV DNA in immunosuppressed patients 
(6,7). 
PCR provides a specific, rapid and sensitive means for 
the detection of viral genomes and may be used in routine 
diagnosis (3,5,6,8,9). 
We have employed the PCR technique for the detection 
of EBV in blood samples from various groups such as kidney 
and heart transplanted patients, AIDS patients and patients 
with infectious mononucleosis, Hodgkin's disease, and 
different lymphomas. 
Materials and methods 
DNA exraction. DNA was extracted from leukocytes from 
the blood of 65 immunosuppressed patients. 3-5 ml of each 
blood sample were diluted with equal volume of 0.9% NaCl. 
The mixture was overlaid onto an equal volume of 
Lymphoprep (Nycomed AS). Samples were then centrifuged 
at 1,800 rpm for 35 min and the white cell layer was 
collected. Cells were washed twice with 0.9% NaCl. 400 μΐ 
of TES (10 mM Tris HCl, pH 8.0, 1 mM EDTA, 0.1% SDS) 
containing 100 μg/ml Proteinase Κ was added to the 
resulting pellet. After one hour of incubation at 60°C, fresh 
Proteinase Κ was added at concentration 100 μg/ml and 
incubation was continued for another hour. Samples were 
then extracted with equal volume of phenol, 
phenol/chloroform and chloroform. DNA was precipitated 
with the addition of 20 μΐ 5 M NaCl and 1 ml ethanol. The 
samples were stored at -20°C overnight. DNA was recovered 
by centrifugation at 13,000 rpm for 15 min at 4°C, washed 
with 70% ethanol and the pellet was resuspended in 50-100 μΐ 
distilled water. 
Oligonucleotide primers and PCR. One set of primers was 
used for the amplification of a 375bp region of the EBV 
EcoRI Β fragment of the virus genome (10,11) (Table I). 
PCR was performed with 1-3 μg genomic DNA in 100 μΐ 
of the reaction containing buffer (Perkin-Elmer Cetus),10X 
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Table I. Primers used for the amplification of a 375bp fragment from the EBV genome. 
Primers Sequences Location on EBV genome 
Nucleotide no. 
EBV 1 
EBV 2 
5' GTGTGCGTCGTGCCGGGGCAGCCAC 3' 
5' ACCTGGGAGGGCCATCGCAAGCTCC 3' 
102669-102694 
103019-103044 
10 mM Tris HCl at pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 
0.001% gelatin, 200 mM dNTPs, 40 pmoles of each primer 
and 2.5U of Taq polymerase (Advanced Biotechnologies). 
Before the addition of Taq polymerase, samples were heated 
at 98°C for 5 min. Amplification was performed in a Perkin 
Elmer Cetus Thermal Cycler with the following parameters: 
denaturation at 95 °C for 1 min, annealing and extension at 
72°C for 1 min, for 35 cycles. 20 μΐ aliquots of the 
amplification products were analysed on a 2% agarose gel 
and visualised under UV illumination after staining with 
ethidium bromide. 
Restriction endonuclease cleavage. 10 μΐ aliquots of the PCR 
product were separately digested with 20U of Hindlll, BstNI 
and PvuII (New England Biolabs), following the conditions 
recommended by the suppliers. 
1 2 3 4 5 6 7 8 
Figure 1. EBV amplification products analysed in a 2% agarose gel stained 
with ethidium bromide. The presence of a 375bp band indicates the presence 
of EBV DNA in the sample. Lane 1: pUC18/HaeIII molecular weight 
marker. Lane 2: negative control, lane 3: positive control, lanes 5, 6 and 8: 
positive samples, lanes 4 and 7: negative samples. 
Results 
Sixty-five blood specimens, including samples of infectious 
mononucleosis, Hodgkin's disease, AIDS, different 
leukemias and lymphomas and samples from heart and 
kidney transplant patients were examined. Positivity of the 
samples were judged by the presence of a 375bp following 
the electrophoretic analysis of the PCR products (Fig. 1 ). 
EBV-specific sequences were amplified in the blood of 7 
out of 21 kidney transplant patients, 2 out of 10 heart 
transplant patients and all individuals with infectious 
mononucleosis and angioblastic lymphathenopathy. EBV 
was not detected in 4 patients with Hodgkin's disease. 
Additionally, EBV was detected in 1 out of 6 leukemias and 
lymphomas, 3 out of 17 patients with high titres of IgG and 
IgM and 1 out of 4 AIDS patients. The results of EBV 
detection by PCR are summarised in Table III. 
To ensure the specificity of the reaction, PCR products 
were separately digested with Hindlll, BstNI and PvuII. The 
cleavage sites of the enzymes and the expected restriction 
fragments are shown in Table II. The digestion products were 
analysed on a 2% agarose gel and visualised under UV 
illumination after staining with ethidium bromide (Fig. 2). 
All EBV amplified sequences showed the expected 
restriction fragments. 
Discussion 
EBV infects Β lymphocytes leading to their cellular 
proliferation that is controlled by a Τ lymphocyte response. 
Thereby, infection with EBV has been described as a viral 
process that generates a prominent immune response. A 
prominent T-lymphocyte proliferation occuring in response 
to EBV-carrying Β lymphocytes results in infectious 
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Figure 2. Amplification products of the digested EBV-specific sequence. 
Lane 1: EBV positive sample, lanes 2, 3 and 4: EBV band digested with 
Hindlll, BstNI and PvuII respectively. 
Table II. Restriction endonuclease enzymes and their sites of 
cleavage of EBV-specific sequence. 
Restriction enzyme Cleavage site Restriction products 
bp 
Hindlll 
BstNI 
PvuII 
A/AGCTT 
CC/AGG 
CAG/CTG 
214, 161 
130,241,4 
199, 176 
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Table III. Detection of EBV by PCR. References 
Study cases 
Kidney transplants 
Heart transplants 
Angioblastic lymphathenopathy 
Leukemias and lymphomas 
AIDS patients 
High IgG, IgM titres 
Hodgkin's disease 
Infectious mononucleosis 
Total 
No. of 
patients 
2I 
10 
l 
6 
4 
17 
4 
2 
65 
EBV 
positive 
7 
2 
1 
2 
1 
3 
0 
2 
18 
mononucleosis. Lymphoproliferative disorders following 
organ transplantation or AIDS represent an unchecked 
proliferation of EBV infected B-lymphocytes (7). 
The diagnosis of EBV infections has generally been 
based on clinical features, a Monospot test or on serological 
evidence. 
The PCR technique, because of its ability to detect 
reduced numbers of viral copies, is an important diagnostic 
tool in diseases caused by EBV to immunosuppressed and 
immunocompromised individuals. It is a rapid, specific and 
sensitive method and is independent of the humoral immune 
status of the patients. The absence of increasing levels of 
antibody to EBV in some patients may reflect impaired 
humoral immunity rather than lack of active infection. 
In transplant recipients taking immunosuppressive agents 
post-transplant lymphoproliferative disorders have emerged 
as potentially life-threatening complications. Early 
recognition of these disorders is important because many 
patients would recover with modulation of their immuno­
suppressive therapy. 
Finally, establishing the presence of EBV has prognostic 
importance because EBV-associated tumor progression can 
be reversible upon reduction or discontinuation of 
immunosuppression. 
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